Tumor angiogenesis and vascular normalization: alternative therapeutic targets

By C. Viallard, B. Larrivée. Angiogenesis, 2017

1,255 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022, background): “Angiogenesis inhibitor blocks these proangiogenic pathways, promotes vessel normalization, improves tumor perfusion and oxygenation, restores the hypoxic TME, and enhances drug delivery [100, 101].”
Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “stimulation, inflammatory response, oncogene mutation, and drug treatment to aggravate tumor angiogenesis and further promote tumor invasion and metastasis.(26) Up to now, although a significant number of research has been devoted to anti-cancer therapy to overcome this incurable and lethal disease,”
Targeting Tumor Microenvironment for Cancer Therapy (2019, background): “One example is the phase 1 trial NCT02665416 that evaluates the combination of Selicrelumab, a CD40 agonist, with Vanucizumab, a bispecific antibody that targets simultaneously ANGPT2 and VEGF-A versus the action of Selicrelumab with Bevacizumab, an anti-VEGF antibody, for treatment of advanced soli”